Cidara Therapeutics Valuation
| CDTX Stock | USD 19.59 0.90 4.82% |
At this time, the firm appears to be overvalued. Cidara Therapeutics shows a prevailing Real Value of $13.13 per share. The current price of the firm is $19.59. Our model approximates the value of Cidara Therapeutics from analyzing the firm fundamentals such as return on equity of -1.53, and Profit Margin of (2.11) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cidara Therapeutics' valuation include:
Price Book 1.139 | Enterprise Value 8.3 M | Enterprise Value Ebitda (1.64) | Price Sales 2.4448 | Forward PE 5.7504 |
Overvalued
Today
Please note that Cidara Therapeutics' price fluctuation is slightly risky at this time. Calculation of the real value of Cidara Therapeutics is based on 3 months time horizon. Increasing Cidara Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cidara Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cidara Stock. However, Cidara Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 19.59 | Real 13.13 | Target 5.6 | Hype 19.84 |
The intrinsic value of Cidara Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cidara Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cidara Therapeutics helps investors to forecast how Cidara stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cidara Therapeutics more accurately as focusing exclusively on Cidara Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cidara Therapeutics' intrinsic value based on its ongoing forecasts of Cidara Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cidara Therapeutics' closest peers.
Cidara Therapeutics Cash |
|
Cidara Valuation Trend
Analysing the historical paterns of Cidara Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Cidara Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Cidara Therapeutics Total Value Analysis
Cidara Therapeutics is currently anticipated to have valuation of 8.26 M with market capitalization of 131.7 M, debt of 4.88 M, and cash on hands of 53.08 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cidara Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.26 M | 131.7 M | 4.88 M | 53.08 M |
Cidara Therapeutics Investor Information
About 52.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.14. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cidara Therapeutics recorded a loss per share of 23.9. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 24th of April 2024. Based on the key indicators related to Cidara Therapeutics' liquidity, profitability, solvency, and operating efficiency, Cidara Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Cidara Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cidara Therapeutics has an asset utilization ratio of 95.34 percent. This suggests that the Company is making $0.95 for each dollar of assets. An increasing asset utilization means that Cidara Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Cidara Therapeutics Ownership Allocation
The market capitalization of Cidara Therapeutics is $131.7 Million. Over half of Cidara Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Cidara Therapeutics Profitability Analysis
The company reported the previous year's revenue of 63.91 M. Net Loss for the year was (22.93 M) with loss before overhead, payroll, taxes, and interest of (11.23 M).About Cidara Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Cidara Therapeutics. We calculate exposure to Cidara Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cidara Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 62.4 M | 65.5 M | |
| Pretax Profit Margin | (0.35) | (0.37) | |
| Operating Profit Margin | (0.38) | (0.40) | |
| Net Loss | (0.36) | (0.38) | |
| Gross Profit Margin | 0.98 | 1.02 |
Cidara Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 4.4 M | |
| Forward Price Earnings | 5.7504 |
Cidara Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Cidara Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Cidara we look at many different elements of the entity such as Cidara's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Cidara Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Cidara Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Cidara Therapeutics' worth.Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.